欧盟发布转基因大豆BPS-CV127-9新测序信息的风险评估

 

    转基因生物（GMO）小组此前就转基因大豆BPS - CV127 - 9预期用途对人类和动物健康及环境的潜在影响做了风险评估，发现这种大豆与传统大豆和商业大豆品种一样安全和有营养。2018年2月16日，应欧盟委员会要求，欧盟食品安全局分析转基因大豆BPS - CV127 - 9的新核酸测序数据和更新的生物信息学数据，并指出转基因大豆BPS - CV127 - 9安全小组先前的结论是否仍然有效。经过评估，新的测序数据和对新序列进行的生物信息学分析没有引起安全问题。因此，EFSA得出结论，大豆BPS - CV127 - 9的原始风险评估仍然有效。

 

    部分原文报道如下：

 

    The GMO Panel has previously assessed genetically modified （GM） soybean BPS‐CV127‐9. This soybean was found to be as safe and nutritious as its conventional counterpart and commercial soybean varieties with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 16 February 2018, European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soybean BPS‐CV127‐9 and to indicate whether the previous conclusions of the GMO Panel on safety of GM soybean BPS‐CV127‐9 remain valid. The new sequencing data indicated a two nucleotide difference in the unannotated Arabidopsis genomic DNA sequence downstream of the 3′ untranslated region of the ahasl （also referred to as csr1‐2） gene as compared to the sequencing data originally provided. One of these nucleotide differences reported in the new nucleic acid sequencing data from GM soybean event BPS‐CV127‐9 was shown to be already present in the original plant material used for the risk assessment. However, for the other nucleotide difference reported, no evidence could be provided to differentiate between a sequencing error and point‐mutation. With the exception of bioinformatics analyses, the studies performed for the risk assessment of the single event soybean BPS‐CV127‐9 remain valid. The new sequencing data and the bioinformatics analyses performed on the new sequence did not give rise to safety issues. Therefore, EFSA concludes that the original risk assessment of soybean BPS‐CV127‐9 remains valid.